INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$0.35
+0.01 (+3.01%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| EPS | — | — | — |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| Rev Growth | +8.4% | -9.6% | +19.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.02M | 2.04M | 2.26M |
| Total Equity | 6.25M | 6.09M | 6.50M |
| D/E Ratio | 0.32 | 0.33 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |